TY - JOUR
T1 - Biopharmaceutical Revolution in Saudi Arabia
T2 - Progress and Development
AU - Alzahrani, Rihana
AU - Harris, Elaine
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/3
Y1 - 2021/3
N2 - Purpose: This paper aimed to analyze the situation of the biopharmaceutical industry in Saudi Arabia to improve the situation in a way that achieves high levels of development similar to those in Europe, the United States of America (USA), and Japan. Methods: To achieve the objective of the study, the authors surveyed 18 out of 21 Saudi pharmaceutical companies that have received licensing for manufacturing from the Saudi Food and Drug Authority (SFDA) to diagnose the situation of manufacturing in relation to biopharmaceuticals. An interview with SFDA officials was carried out as a supplement to the survey. Results: Findings revealed a serious lack of manufacturing of biopharmaceuticals in Saudi Arabia. In addition, knowledge of biopharmaceutical practice in upstream and downstream bioprocessing is poor. The analysis of interviews revealed some progress in biopharmaceuticals in Saudi Arabia, namely, applications to manufacture insulin and vaccines. Conclusion: On the basis of the findings, recommendations were made to develop the situation of biopharmaceutics in Saudi Arabia.
AB - Purpose: This paper aimed to analyze the situation of the biopharmaceutical industry in Saudi Arabia to improve the situation in a way that achieves high levels of development similar to those in Europe, the United States of America (USA), and Japan. Methods: To achieve the objective of the study, the authors surveyed 18 out of 21 Saudi pharmaceutical companies that have received licensing for manufacturing from the Saudi Food and Drug Authority (SFDA) to diagnose the situation of manufacturing in relation to biopharmaceuticals. An interview with SFDA officials was carried out as a supplement to the survey. Results: Findings revealed a serious lack of manufacturing of biopharmaceuticals in Saudi Arabia. In addition, knowledge of biopharmaceutical practice in upstream and downstream bioprocessing is poor. The analysis of interviews revealed some progress in biopharmaceuticals in Saudi Arabia, namely, applications to manufacture insulin and vaccines. Conclusion: On the basis of the findings, recommendations were made to develop the situation of biopharmaceutics in Saudi Arabia.
KW - Biopharmaceutics
KW - Companies
KW - Development
KW - SDFA
KW - Saudi Arabia
UR - https://www.scopus.com/pages/publications/85078494623
U2 - 10.1007/s12247-020-09429-1
DO - 10.1007/s12247-020-09429-1
M3 - Article
AN - SCOPUS:85078494623
SN - 1872-5120
VL - 16
SP - 110
EP - 123
JO - Journal of Pharmaceutical Innovation
JF - Journal of Pharmaceutical Innovation
IS - 1
ER -